Church & Dwight Has Growth Hero In Hero Acne Products, Optimism For Broader Sales Stabilization
Executive Summary
Reported revenues for January-March up 10.2% to $1.43bn, with around half the growth coming on sales of Hero Mighty Patch acne treatments. Price increases drove Q1 revenue growth across other categories with volume largely flat.
You may also be interested in...
Whether Higher Sales Or Lower Volumes, Price Increases Make Presence Known For P&G And C&D
Both health, wellness and beauty product marketers on report increased prices helped drive revenue growth during April-June period while also factoring in lower sales volumes.
US Q2 Consumer Health Earnings Preview: Two Firsts On Table For Perrigo, One For Kenvue
Perrigo will note regulatory approval for Opill as first US OTC oral contraceptive in first earnings briefing with Patrick Lockwood-Taylor at helm. Other firsts in sector will be Kenvue’s 20 July results being its first since spin-out from J&J in May and Bausch + Lomb’s first quarterly results under CEO Saunders.
Flawless Deal Revealed Flaw In C&D’s M&A Criteria
“You won't be seeing us buying devices in the future,” says CEO Matthew Farrell. Acquisitions won’t have lower profile in growth strategy and it’s investing behind boosting returns from its most recent additions, acne patch firm Hero Cosmetics and TheraBreath mouthwashes, toothpastes and lozenges.